Graves' disease in children: clinical aspects and outcome

被引:12
作者
Boiko, J
Leger, J
Raux-Demay, MC
Cabrol, S
Le Bouc, Y
Czernichow, P
机构
[1] Hop Robert Debre, Serv Endocrinol & Diabetol Pediat, F-75019 Paris, France
[2] Hop Armand Trousseau, Serv Explorat Fonct Endocriniennes, F-75571 Paris 12, France
来源
ARCHIVES DE PEDIATRIE | 1998年 / 5卷 / 07期
关键词
Graves' disease; thyroid antagonist; follow-up studies; child;
D O I
10.1016/S0929-693X(98)80052-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Patients and methods. - The initial symptomatology and long-term effects of antithyroid drug treatment are reported in children aged 11.7 +/- 3.2 years (52 girls,16 boys) with hyperthyroidism due to Graves' disease. Results, - A family history of thyroid pathology was found in half of the cases: 7% (five out of 68) of our patients have had another autoimmune disorder associated with hyperthyroidism. The most frequent and permanent clinical symptoms at diagnosis were goiter and tachycardia. Antithyroid drug treatment was always proposed at first line and resulted in a rapid decrease in clinical and biological signs of hyperthyroidism. Subtotal thyroidectomy (n = 19) was mostly performed because of non-compliance or recurrence of hyperthyroidism after medical treatment withdrawal. Significant adverse reaction (leukoneutropenia) was observed in only one patient. Survival remission times analysis (remission being defined as clinical and biological euthyroidism for more than I year after antithyroid drug withdrawal) realised in 50 subjects followed up for at least 2.5 years showed complete remission in 55% of the patients treated exclusively medically (n = 27), when lost to follow-up or surgically treated subjects were considered as incomplete observations. On the whole studied population (n = 50), the remission rate was of 30% (n = 15) with an average follow-up period after medical therapy withdrawal of 5.2 +/- 3.0 years (range: 1.4-12.3 years). At present, ten out of 15 can be considered as healed (remission time for at least 2.5 years). Moreover, according to survival analysis, 75% of the remissions have a probability to occur in a delay of 4.6 +/- 1.0 years after the beginning of medical treatment. Conclusion. - In this population, no remission after 7 years of antithyroid drug therapy was observed. Remission predictive factors remain to be defined. (C) 1998, Elsevier, Paris.
引用
收藏
页码:722 / 730
页数:9
相关论文
共 35 条
[1]   ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION [J].
ALLANNIC, H ;
FAUCHET, R ;
ORGIAZZI, J ;
MADEC, AM ;
GENETET, B ;
LORCY, Y ;
LEGUERRIER, AM ;
DELAMBRE, C ;
DERENNES, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) :675-679
[2]  
Barnes H V, 1977, J Pediatr, V91, P313, DOI 10.1016/S0022-3476(77)80843-3
[3]   GROWTH IN THYROTOXICOSIS [J].
BUCKLER, JMH ;
WILLGERODT, H ;
KELLER, E .
ARCHIVES OF DISEASE IN CHILDHOOD, 1986, 61 (05) :464-471
[4]  
CLARK JD, 1995, J NUCL MED, V36, P442
[5]  
COLLEN RJ, 1980, PEDIATRICS, V65, P550
[6]   ANTITHYROID DRUGS [J].
COOPER, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (21) :1353-1362
[7]  
DAVID M, 1983, LYON MED, V250, P49
[8]   JUVENILE GRAVES-DISEASE - USEFULNESS AND LIMITATIONS OF THYROTROPIN RECEPTOR ANTIBODY DETERMINATIONS [J].
FOLEY, TP ;
WHITE, C ;
NEW, A .
JOURNAL OF PEDIATRICS, 1987, 110 (03) :378-386
[9]   LONG-TERM FOLLOW-UP OF TREATMENT OF THYROTOXICOSIS BY 3 DIFFERENT METHODS [J].
FRANKLYN, JA ;
DAYKIN, J ;
DROLC, Z ;
FARMER, M ;
SHEPPARD, MC .
CLINICAL ENDOCRINOLOGY, 1991, 34 (01) :71-76
[10]  
FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731